We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

46 hedge funds and large institutions have $154M invested in Orchestra BioMed in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

17% more capital invested

Capital invested by funds: $132M → $154M (+$22.3M)

5% more funds holding

Funds holding: 44 → 46 (+2)

1.48% less ownership

Funds ownership: 60.24% → 58.76% (-1.5%)

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

Holders
46
Holders Change
+2
Holders Change %
+4.55%
% of All Funds
0.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
+$575K
2
TD Asset Management
TD Asset Management
Ontario, Canada
+$528K
3
ECM
ExodusPoint Capital Management
New York
+$340K
4
MF
Magnetar Financial
Illinois
+$76.4K
5
WP
Woodline Partners
California
+$42.2K

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$2.78M
2
PC
Periscope Capital
Ontario, Canada
-$1.03M
3
GPCM
Granite Point Capital Management
Massachusetts
-$593K
4
GL
Governors Lane
New York
-$499K
5
MS
Maven Securities
Jersey
-$379K
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
26
Periscope Capital
Ontario, Canada
$1.4M -$1.03M -90,539 -45%
MIM
27
Monashee Investment Management
Massachusetts
$1.28M – – –
PVI
28
Pura Vida Investments
New York
$1.28M – – –
SFM
29
Sphera Funds Management
Israel
$1.28M – – –
MS
30
Maven Securities
Jersey
$1.19M -$379K -33,285 -27%
SCM
31
Shaolin Capital Management
Florida
$641K – – –
SCM
32
Suvretta Capital Management
New York
$641K – – –
GPCM
33
Granite Point Capital Management
Massachusetts
$615K -$593K -52,000 -52%
HI
34
HBK Investments
Texas
$612K – – –
BCP
35
Berylson Capital Partners
Massachusetts
$594K – – –
TD Asset Management
36
TD Asset Management
Ontario, Canada
$594K +$528K +46,339 New
MF
37
Magnetar Financial
Illinois
$406K +$76.4K +6,702 +27%
ECM
38
ExodusPoint Capital Management
New York
$382K +$340K +29,800 New
Millennium Management
39
Millennium Management
New York
$359K -$169K -14,837 -35%
Alyeska Investment Group
40
Alyeska Investment Group
Illinois
$320K -$2.28K -200 -0.8%
OWP
41
Old Well Partners
North Carolina
$183K – – –
6CM
42
683 Capital Management
New York
$128K – – –
RCM
43
Rivernorth Capital Management
Florida
$128K – – –
ACM
44
Altium Capital Management
New York
$128K +$114K +10,000 New
WRBC
45
W.R. Berkley Corp
Connecticut
$127K – – –
PAMP
46
Polar Asset Management Partners
Ontario, Canada
– -$2.78M -252,500 Closed
MI
47
MMCAP International
Cayman Islands
– -$288K -26,207 Closed
Marshall Wace
48
Marshall Wace
United Kingdom
– -$224K -20,355 Closed
SRCM
49
Sage Rock Capital Management
New York
– -$201K -18,285 Closed
UBS Group
50
UBS Group
Switzerland
– +$308 +27 New
1
2

OBIO Hedge Fund Activity: Q4 2020 in Review

46 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2020, worth a combined $154M — up 17% from $132M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new OBIO positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 9 trimmed.

The largest buyer was K2 Principal Fund, adding an estimated $575K. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $2.78M sold.

  • 46 institutional investors held Orchestra BioMed (OBIO) as of Q4 2020, up from 44 in Q3 2020.
  • Funds reported $154M of Orchestra BioMed stock for Q4 2020, up 17% quarter-over-quarter.
  • 6 funds opened new Orchestra BioMed positions in Q4 2020 and 4 closed out, a net change of +2 holders.
  • The largest Orchestra BioMed buyer in Q4 2020 was K2 Principal Fund, an estimated $575K added.
  • The largest Orchestra BioMed seller in Q4 2020 was Polar Asset Management Partners, an estimated $2.78M sold.

Based on aggregated 13F filings for Q4 2020.